, Tracking Stock Market Picks
Enter Symbol:
Intermune, Inc. (ITMN) [hlAlert]

up 702.38 %

Intermune, Inc. (ITMN) rated Outperform with price target $14 by Mehta Partners

Posted on: Wednesday,  Jun 23, 2010  10:25 AM ET by Mehta Partners

Mehta Partners rated Outperform Intermune, Inc. (NASDAQ: ITMN) on 06/23/2010, when the stock price was $9.21. Since
then, Intermune, Inc. has gained 702.39% as of 09/26/2014's recent price of $73.90.
If you would have followed this Mehta Partners's recommendation on ITMN, you would have gained 702.38% of your investment in 1556 days.

InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.

The reputation of Mehta Partners rests on a body of work that began in 1980s with the aim of "maintaining a birds-eye view of the pharma, biotech and healthcare industry worldwide." Viren Mehta, founder and managing partner of Mehta Partners, formulated this objective and emphasized that the Biotechnology and Pharmaceutical segments are ultimately indistinguishable parts of the BioPharma industry; and that BioPharma is a truly global industry that is best understood when viewed from a worldwide perspective.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/23/2010 10:25 AM Buy
9.21 14.00
as of 12/31/2010
1 Week down  -5.29 %
1 Month up  179.37 %
3 Months up  157.63 %
1 YTD up  280.99 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy